

Part VI: Summary of the risk management plan

Summary of risk management plan for Bicalutamide 150 mg film-coated tablets

This is a summary of the risk management plan (RMP) for bicalutamide 150 mg film-coated tablets. The RMP details important risks of bicalutamide 150 mg film-coated tablets, how these risks can be minimised, and how more information will be obtained about bicalutamide 150 mg film-coated tablet's risks and uncertainties (missing information).

Bicalutamide 150 mg film-coated tablet's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how bicalutamide 150 mg film-coated tablets should be used.

Important new concerns or changes to the current ones will be included in updates of bicalutamide 150 mg film-coated tablet's RMP.

I. The medicine and what it is used for

Bicalutamide is indicated either alone or as adjuvant to radical prostatectomy or radiotherapy in patients with locally advanced prostate cancer at high risk for disease progression.

Bicalutamide is also indicated for the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

It contains Bicalutamide as the active substance and it is given by oral route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of bicalutamide 150 mg film-coated tablets, together with measures to minimise such risks and the proposed studies for learning more about bicalutamide 150 mg film-coated tablet's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;

- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment and signal management activity, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of important risks and missing information

Important risks of bicalutamide 150 mg film-coated tablets are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of bicalutamide 150 mg film-coated tablets. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

| List of important risks and missing information | |
|--|---|
| Important identified risks | <ul style="list-style-type: none"> • Hypersensitivity reactions (including anaphylactic reactions) • Hepatotoxicity (including hepatic failure) • Photosensitivity • Interstitial lung disease • Drug interactions (co-administration with terfenadine, astemizole or cisapride) |
| Important potential risks | <ul style="list-style-type: none"> • Cardiac disease (cardiac failure, myocardial infarction) • QT interval prolongation and Torsade de Pointes |

| | |
|---------------------|---|
| | <ul style="list-style-type: none">• Drug interactions |
| Missing information | <ul style="list-style-type: none">• None |

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of bicalutamide 150 mg film-coated tablets.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for bicalutamide 150 mg film-coated tablets.